All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Positive topline results from a phase II trial of antroquinonol for patients with AML
On November 26, 2020, a press release on topline results from a phase II trial (NCT03823352) of antroquinonol in adult patients with acute myeloid leukemia (AML) was released, showing encouraging overall response rates and a safe tolerability profile.1
Antroquinonol1,2
- Is an ubiquinone derivative of the fungus Antrodia camphorate, which inhibits the enzymatic activity of isoprenyltransferases, thereby interfering with the Ras/Rho-PI3K-Akt-mTOR pathway to induce apoptosis and autophagy.
- Received U.S. Food and Drug Administration (FDA) orphan drug designation for the treatment of AML, hepatocellular cancer, and pancreatic cancer in 2015, and is also currently being tested clinically for efficacy in the treatment of COVID-19.
NCT03823352
Study design3
- Phase IIa, open-label, non-randomized study evaluating the safety and efficacy of antroquinonol in 12 adult patients (18–70 years) with relapsed AML or newly diagnosed AML ineligible for intensive treatment
- Dose: 200 mg twice daily on Day 1 for 4 weeks
- Primary outcome: Overall response rate (complete response/complete response with incomplete count recovery [CR/CRi])
- Secondary outcomes: % of patients alive at 4 weeks and at 24 weeks
Topline Results1
- CR/CRi: 50%
- 80% of patients achieved a blast cell count of < 5%
- 90% of patients did not require blood transfusions during the trial period
- 100% of patients were alive at Week 24
- No serious adverse effects were reported
Based on these results, plans for future trials of antroquinonol in the frontline AML setting are ongoing and may expand to other indications, such as multiple myeloma, chronic myelogenous leukemia, and pediatric leukemia.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
How important to you is the turnaround time for genetic testing in guiding your initial treatment decisions?